PD-L1 expression

The role of the pathologist in the field of lung cancer 1:44
The role of the pathologist in the field of lung cancer
Keith Kerr • 11 Apr 2018
Problems with PD-L1 expression testing in patients with NSCLC 3:37
Problems with PD-L1 expression testing in patients with NSCLC
Keith Kerr • 11 Apr 2018
Novel therapies for the treatment of NSCLC: immunotherapy and targeted agents 2:10
Novel therapies for the treatment of NSCLC: immunotherapy and targeted agents
Federico Cappuzzo • 11 Apr 2018
ATLANTIC: durvalumab in the fight against NSCLC 1:28
ATLANTIC: durvalumab in the fight against NSCLC
Marina Garassino • 1 Jun 2018
KEYNOTE-042: revolutionizing lung cancer treatment with pembrolizumab monotherapy 1:14
KEYNOTE-042: revolutionizing lung cancer treatment with pembrolizumab monotherapy
David Carbone • 1 Jun 2018
Trial updates in mRCC from ASCO: KEYNOTE-427, RESORT, E2810 & IMmotion151 4:20
Trial updates in mRCC from ASCO: KEYNOTE-427, RESORT, E2810 & IMmotion151
Toni Choueiri • 1 Jun 2018
Guiding NSCLC treatment with biomarkers 1:13
Guiding NSCLC treatment with biomarkers
Alastair Greystoke • 14 Jun 2018
EMA restrict pembrolizumab/atezolizumab usage in urothelial cancer 2:18
EMA restrict pembrolizumab/atezolizumab usage in urothelial cancer
Thomas Powles
The role of PD-L1: is it accurate enough as a biomarker for immunotherapy response? 3:50
The role of PD-L1: is it accurate enough as a biomarker for immunotherapy response?
Jacob Kettle • 21 Mar 2018
Checkpoint inhibitors in small cell lung cancer (SCLC) 1:18
Checkpoint inhibitors in small cell lung cancer (SCLC)
David Spigel • 4 Dec 2016
VJOncology VJOncology is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter

Subscribe now
The content of VJOncology is intended for healthcare professionals